The 30-Year Plant, the 3-Year Forecast: Pharma’s Infrastructure Risk Problem

On this episode of The Regulatory Mix, the discussion focuses on a growing strategic problem across the pharmaceutical industry: companies are making 20- and 30-year infrastructure investments in a world where demand forecasts, technologies, regulations, and geopolitical assumptions can change in only a few years.

The episode examines major investments in peptide, API, and antibiotic manufacturing as companies race to secure capacity and reduce supply-chain dependence. Projects from Bachem, Aurobindo, and other manufacturers demonstrate the scale of the bet being made on future demand. But the strategic question is no longer simply whether additional capacity is needed. It is whether today’s highly specialized assets will still be commercially and technologically relevant by the time they are fully validated and operating at scale.

That tension is becoming more important as regulators increase their focus on supply-chain resilience. In Europe, shortage prevention planning is placing greater responsibility on marketing authorization holders to understand vulnerabilities before a disruption occurs. In the United States, FDA organizational changes and continued updates to product-specific guidance reflect an environment in which regulatory expectations can evolve far faster than physical manufacturing infrastructure.

The discussion also highlights why supply resilience cannot be separated from manufacturing quality. Recent FDA findings at sterile manufacturing facilities demonstrate the danger of allowing business urgency to override process understanding. Passing sterility tests, environmental monitoring, or final product testing does not compensate for recurring contamination events or weak investigations. Sterility assurance remains fundamentally process-based, and repetitive deviations that are explained away rather than understood can become evidence of a much larger quality-system failure.

The same principle applies at the boardroom level. Organizations can create strategic risk when assumptions become progressively more optimistic simply to justify a major capital project or acquisition. Leadership teams should continually challenge which assumptions would leave the organization trapped if demand changes, a new modality emerges, regulations shift, or a competitor develops a fundamentally easier manufacturing route.

The takeaway is that pharmaceutical resilience is no longer just about building more capacity. It is about building adaptable capacity supported by strong quality systems, diversified supply chains, regulatory awareness, and the ability to change direction before yesterday’s strategic advantage becomes tomorrow’s stranded asset.

Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.

Disclosure: Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.